nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—CYP3A4—Fingolimod—multiple sclerosis	0.117	0.246	CbGbCtD
Dantrolene—CYP3A4—Methylprednisolone—multiple sclerosis	0.0753	0.158	CbGbCtD
Dantrolene—CYP3A4—Triamcinolone—multiple sclerosis	0.0571	0.12	CbGbCtD
Dantrolene—CYP3A4—Mitoxantrone—multiple sclerosis	0.055	0.116	CbGbCtD
Dantrolene—CYP3A4—Betamethasone—multiple sclerosis	0.049	0.103	CbGbCtD
Dantrolene—CYP3A4—Prednisolone—multiple sclerosis	0.0483	0.102	CbGbCtD
Dantrolene—CYP3A4—Prednisone—multiple sclerosis	0.0457	0.0959	CbGbCtD
Dantrolene—CYP3A4—Dexamethasone—multiple sclerosis	0.0285	0.0599	CbGbCtD
Dantrolene—RYR3—medulla oblongata—multiple sclerosis	0.0126	0.11	CbGeAlD
Dantrolene—RYR3—midbrain—multiple sclerosis	0.0115	0.1	CbGeAlD
Dantrolene—RYR3—spinal cord—multiple sclerosis	0.0112	0.098	CbGeAlD
Dantrolene—RYR3—nervous system—multiple sclerosis	0.00948	0.0826	CbGeAlD
Dantrolene—RYR3—central nervous system—multiple sclerosis	0.00912	0.0795	CbGeAlD
Dantrolene—RYR1—medulla oblongata—multiple sclerosis	0.00905	0.0789	CbGeAlD
Dantrolene—RYR3—cerebellum—multiple sclerosis	0.00892	0.0777	CbGeAlD
Dantrolene—RYR1—midbrain—multiple sclerosis	0.00827	0.0721	CbGeAlD
Dantrolene—RYR3—brain—multiple sclerosis	0.00724	0.0631	CbGeAlD
Dantrolene—RYR1—nervous system—multiple sclerosis	0.0068	0.0593	CbGeAlD
Dantrolene—RYR1—central nervous system—multiple sclerosis	0.00655	0.0571	CbGeAlD
Dantrolene—RYR1—cerebellum—multiple sclerosis	0.0064	0.0558	CbGeAlD
Dantrolene—RYR1—brain—multiple sclerosis	0.0052	0.0453	CbGeAlD
Dantrolene—RYR3—MFAP5-mediated ovarian cancer cell motility and invasiveness—MAPK1—multiple sclerosis	0.00219	0.0974	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—RGS1—multiple sclerosis	0.00183	0.0816	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—RGS1—multiple sclerosis	0.00177	0.0791	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—TNFRSF1A—multiple sclerosis	0.00158	0.0704	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—RGS1—multiple sclerosis	0.00135	0.0602	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—RGS1—multiple sclerosis	0.00131	0.0583	CbGpPWpGaD
Dantrolene—CYP3A4—nervous system—multiple sclerosis	0.00118	0.0103	CbGeAlD
Dantrolene—CYP3A4—central nervous system—multiple sclerosis	0.00114	0.00992	CbGeAlD
Dantrolene—RYR3—Alzheimers Disease—FAS—multiple sclerosis	0.00109	0.0484	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—APOE—multiple sclerosis	0.000997	0.0444	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000802	0.0357	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—IL1B—multiple sclerosis	0.000635	0.0283	CbGpPWpGaD
Dantrolene—Dysgeusia—Triamcinolone—multiple sclerosis	0.000623	0.00161	CcSEcCtD
Dantrolene—Nausea—Cladribine—multiple sclerosis	0.000622	0.00161	CcSEcCtD
Dantrolene—Back pain—Triamcinolone—multiple sclerosis	0.000615	0.00159	CcSEcCtD
Dantrolene—Somnolence—Mitoxantrone—multiple sclerosis	0.000611	0.00158	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000608	0.0271	CbGpPWpGaD
Dantrolene—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000605	0.00156	CcSEcCtD
Dantrolene—Convulsion—Prednisolone—multiple sclerosis	0.000599	0.00155	CcSEcCtD
Dantrolene—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000598	0.00154	CcSEcCtD
Dantrolene—Hypertension—Prednisolone—multiple sclerosis	0.000597	0.00154	CcSEcCtD
Dantrolene—Eosinophilia—Methotrexate—multiple sclerosis	0.000597	0.00154	CcSEcCtD
Dantrolene—Fatigue—Mitoxantrone—multiple sclerosis	0.000593	0.00153	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000591	0.0263	CbGpPWpGaD
Dantrolene—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00059	0.00152	CcSEcCtD
Dantrolene—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000589	0.00152	CcSEcCtD
Dantrolene—Constipation—Mitoxantrone—multiple sclerosis	0.000588	0.00152	CcSEcCtD
Dantrolene—Pain—Mitoxantrone—multiple sclerosis	0.000588	0.00152	CcSEcCtD
Dantrolene—Diarrhoea—Azathioprine—multiple sclerosis	0.000582	0.0015	CcSEcCtD
Dantrolene—Discomfort—Prednisolone—multiple sclerosis	0.000582	0.0015	CcSEcCtD
Dantrolene—Haemoglobin—Prednisone—multiple sclerosis	0.00058	0.0015	CcSEcCtD
Dantrolene—Haemorrhage—Prednisone—multiple sclerosis	0.000577	0.00149	CcSEcCtD
Dantrolene—Erythema—Betamethasone—multiple sclerosis	0.000577	0.00149	CcSEcCtD
Dantrolene—Erythema—Dexamethasone—multiple sclerosis	0.000577	0.00149	CcSEcCtD
Dantrolene—Malaise—Triamcinolone—multiple sclerosis	0.000573	0.00148	CcSEcCtD
Dantrolene—Malaise—Methylprednisolone—multiple sclerosis	0.000572	0.00148	CcSEcCtD
Dantrolene—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000567	0.00146	CcSEcCtD
Dantrolene—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000564	0.00146	CcSEcCtD
Dantrolene—Dizziness—Azathioprine—multiple sclerosis	0.000563	0.00145	CcSEcCtD
Dantrolene—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000562	0.00145	CcSEcCtD
Dantrolene—Convulsion—Triamcinolone—multiple sclerosis	0.000551	0.00142	CcSEcCtD
Dantrolene—Tachycardia—Prednisolone—multiple sclerosis	0.000551	0.00142	CcSEcCtD
Dantrolene—Convulsion—Methylprednisolone—multiple sclerosis	0.00055	0.00142	CcSEcCtD
Dantrolene—Hypertension—Triamcinolone—multiple sclerosis	0.000549	0.00142	CcSEcCtD
Dantrolene—Hypertension—Methylprednisolone—multiple sclerosis	0.000548	0.00142	CcSEcCtD
Dantrolene—Urticaria—Mitoxantrone—multiple sclerosis	0.000546	0.00141	CcSEcCtD
Dantrolene—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000546	0.00141	CcSEcCtD
Dantrolene—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000544	0.0014	CcSEcCtD
Dantrolene—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000544	0.0014	CcSEcCtD
Dantrolene—Myalgia—Triamcinolone—multiple sclerosis	0.000541	0.0014	CcSEcCtD
Dantrolene—Vomiting—Azathioprine—multiple sclerosis	0.000541	0.0014	CcSEcCtD
Dantrolene—Myalgia—Methylprednisolone—multiple sclerosis	0.00054	0.0014	CcSEcCtD
Dantrolene—Drowsiness—Methotrexate—multiple sclerosis	0.000537	0.00139	CcSEcCtD
Dantrolene—Rash—Azathioprine—multiple sclerosis	0.000536	0.00139	CcSEcCtD
Dantrolene—Dermatitis—Azathioprine—multiple sclerosis	0.000536	0.00138	CcSEcCtD
Dantrolene—Depression—Methotrexate—multiple sclerosis	0.000536	0.00138	CcSEcCtD
Dantrolene—Flushing—Prednisone—multiple sclerosis	0.000536	0.00138	CcSEcCtD
Dantrolene—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000535	0.00138	CcSEcCtD
Dantrolene—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000535	0.00138	CcSEcCtD
Dantrolene—Discomfort—Triamcinolone—multiple sclerosis	0.000535	0.00138	CcSEcCtD
Dantrolene—Discomfort—Methylprednisolone—multiple sclerosis	0.000534	0.00138	CcSEcCtD
Dantrolene—Headache—Azathioprine—multiple sclerosis	0.000533	0.00138	CcSEcCtD
Dantrolene—Dry mouth—Triamcinolone—multiple sclerosis	0.000529	0.00137	CcSEcCtD
Dantrolene—Renal failure—Methotrexate—multiple sclerosis	0.000528	0.00136	CcSEcCtD
Dantrolene—Confusional state—Methylprednisolone—multiple sclerosis	0.000522	0.00135	CcSEcCtD
Dantrolene—Malaise—Betamethasone—multiple sclerosis	0.00052	0.00134	CcSEcCtD
Dantrolene—Malaise—Dexamethasone—multiple sclerosis	0.00052	0.00134	CcSEcCtD
Dantrolene—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000519	0.00134	CcSEcCtD
Dantrolene—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000518	0.00134	CcSEcCtD
Dantrolene—Sweating—Methotrexate—multiple sclerosis	0.000515	0.00133	CcSEcCtD
Dantrolene—Haematuria—Methotrexate—multiple sclerosis	0.000512	0.00132	CcSEcCtD
Dantrolene—Insomnia—Prednisolone—multiple sclerosis	0.00051	0.00132	CcSEcCtD
Dantrolene—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000507	0.00131	CcSEcCtD
Dantrolene—Tachycardia—Triamcinolone—multiple sclerosis	0.000506	0.00131	CcSEcCtD
Dantrolene—Nausea—Azathioprine—multiple sclerosis	0.000505	0.00131	CcSEcCtD
Dantrolene—Tachycardia—Methylprednisolone—multiple sclerosis	0.000505	0.00131	CcSEcCtD
Dantrolene—Erythema—Prednisone—multiple sclerosis	0.000502	0.0013	CcSEcCtD
Dantrolene—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000502	0.0013	CcSEcCtD
Dantrolene—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000501	0.00129	CcSEcCtD
Dantrolene—Convulsion—Betamethasone—multiple sclerosis	0.0005	0.00129	CcSEcCtD
Dantrolene—Convulsion—Dexamethasone—multiple sclerosis	0.0005	0.00129	CcSEcCtD
Dantrolene—Hypertension—Dexamethasone—multiple sclerosis	0.000498	0.00129	CcSEcCtD
Dantrolene—Hypertension—Betamethasone—multiple sclerosis	0.000498	0.00129	CcSEcCtD
Dantrolene—Asthenia—Mitoxantrone—multiple sclerosis	0.000493	0.00128	CcSEcCtD
Dantrolene—Myalgia—Dexamethasone—multiple sclerosis	0.000491	0.00127	CcSEcCtD
Dantrolene—Myalgia—Betamethasone—multiple sclerosis	0.000491	0.00127	CcSEcCtD
Dantrolene—Discomfort—Betamethasone—multiple sclerosis	0.000485	0.00125	CcSEcCtD
Dantrolene—Discomfort—Dexamethasone—multiple sclerosis	0.000485	0.00125	CcSEcCtD
Dantrolene—Haemoglobin—Methotrexate—multiple sclerosis	0.000485	0.00125	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—MAPK1—multiple sclerosis	0.000484	0.0216	CbGpPWpGaD
Dantrolene—Pain—Prednisolone—multiple sclerosis	0.000483	0.00125	CcSEcCtD
Dantrolene—Hepatitis—Methotrexate—multiple sclerosis	0.000482	0.00125	CcSEcCtD
Dantrolene—Haemorrhage—Methotrexate—multiple sclerosis	0.000482	0.00125	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000481	0.0214	CbGpPWpGaD
Dantrolene—Vision blurred—Prednisone—multiple sclerosis	0.000474	0.00122	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000473	0.00122	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000472	0.00122	CcSEcCtD
Dantrolene—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000471	0.00122	CcSEcCtD
Dantrolene—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000471	0.00122	CcSEcCtD
Dantrolene—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000471	0.00122	CcSEcCtD
Dantrolene—Insomnia—Triamcinolone—multiple sclerosis	0.000469	0.00121	CcSEcCtD
Dantrolene—Insomnia—Methylprednisolone—multiple sclerosis	0.000468	0.00121	CcSEcCtD
Dantrolene—Ill-defined disorder—Prednisone—multiple sclerosis	0.000466	0.0012	CcSEcCtD
Dantrolene—Feeling abnormal—Prednisolone—multiple sclerosis	0.000465	0.0012	CcSEcCtD
Dantrolene—Visual impairment—Methotrexate—multiple sclerosis	0.000465	0.0012	CcSEcCtD
Dantrolene—Anaemia—Prednisone—multiple sclerosis	0.000464	0.0012	CcSEcCtD
Dantrolene—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000461	0.00119	CcSEcCtD
Dantrolene—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000461	0.00119	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—TNF—multiple sclerosis	0.000461	0.0205	CbGpPWpGaD
Dantrolene—Tachycardia—Betamethasone—multiple sclerosis	0.00046	0.00119	CcSEcCtD
Dantrolene—Tachycardia—Dexamethasone—multiple sclerosis	0.00046	0.00119	CcSEcCtD
Dantrolene—Dyspepsia—Triamcinolone—multiple sclerosis	0.000457	0.00118	CcSEcCtD
Dantrolene—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000456	0.00118	CcSEcCtD
Dantrolene—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000455	0.00118	CcSEcCtD
Dantrolene—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000455	0.00118	CcSEcCtD
Dantrolene—Malaise—Prednisone—multiple sclerosis	0.000453	0.00117	CcSEcCtD
Dantrolene—Anorexia—Betamethasone—multiple sclerosis	0.000449	0.00116	CcSEcCtD
Dantrolene—Anorexia—Dexamethasone—multiple sclerosis	0.000449	0.00116	CcSEcCtD
Dantrolene—Urticaria—Prednisolone—multiple sclerosis	0.000448	0.00116	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000448	0.02	CbGpPWpGaD
Dantrolene—Fatigue—Triamcinolone—multiple sclerosis	0.000447	0.00116	CcSEcCtD
Dantrolene—Fatigue—Methylprednisolone—multiple sclerosis	0.000446	0.00115	CcSEcCtD
Dantrolene—Pain—Triamcinolone—multiple sclerosis	0.000444	0.00115	CcSEcCtD
Dantrolene—Vomiting—Mitoxantrone—multiple sclerosis	0.000437	0.00113	CcSEcCtD
Dantrolene—Convulsion—Prednisone—multiple sclerosis	0.000435	0.00112	CcSEcCtD
Dantrolene—Hypertension—Prednisone—multiple sclerosis	0.000434	0.00112	CcSEcCtD
Dantrolene—Rash—Mitoxantrone—multiple sclerosis	0.000434	0.00112	CcSEcCtD
Dantrolene—Dermatitis—Mitoxantrone—multiple sclerosis	0.000433	0.00112	CcSEcCtD
Dantrolene—Chills—Methotrexate—multiple sclerosis	0.000433	0.00112	CcSEcCtD
Dantrolene—Headache—Mitoxantrone—multiple sclerosis	0.000431	0.00111	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000429	0.00111	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000429	0.00111	CcSEcCtD
Dantrolene—Myalgia—Prednisone—multiple sclerosis	0.000428	0.00111	CcSEcCtD
Dantrolene—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000428	0.0011	CcSEcCtD
Dantrolene—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000427	0.0011	CcSEcCtD
Dantrolene—Insomnia—Betamethasone—multiple sclerosis	0.000426	0.0011	CcSEcCtD
Dantrolene—Insomnia—Dexamethasone—multiple sclerosis	0.000426	0.0011	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000425	0.0189	CbGpPWpGaD
Dantrolene—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000423	0.00109	CcSEcCtD
Dantrolene—Discomfort—Prednisone—multiple sclerosis	0.000423	0.00109	CcSEcCtD
Dantrolene—Erythema—Methotrexate—multiple sclerosis	0.00042	0.00108	CcSEcCtD
Dantrolene—Hypersensitivity—Prednisolone—multiple sclerosis	0.000416	0.00107	CcSEcCtD
Dantrolene—Dyspepsia—Betamethasone—multiple sclerosis	0.000414	0.00107	CcSEcCtD
Dantrolene—Dyspepsia—Dexamethasone—multiple sclerosis	0.000414	0.00107	CcSEcCtD
Dantrolene—Urticaria—Triamcinolone—multiple sclerosis	0.000412	0.00107	CcSEcCtD
Dantrolene—Urticaria—Methylprednisolone—multiple sclerosis	0.000411	0.00106	CcSEcCtD
Dantrolene—Dysgeusia—Methotrexate—multiple sclerosis	0.000411	0.00106	CcSEcCtD
Dantrolene—Body temperature increased—Triamcinolone—multiple sclerosis	0.00041	0.00106	CcSEcCtD
Dantrolene—Anaphylactic shock—Prednisone—multiple sclerosis	0.00041	0.00106	CcSEcCtD
Dantrolene—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000409	0.00106	CcSEcCtD
Dantrolene—Decreased appetite—Dexamethasone—multiple sclerosis	0.000409	0.00106	CcSEcCtD
Dantrolene—Decreased appetite—Betamethasone—multiple sclerosis	0.000409	0.00106	CcSEcCtD
Dantrolene—Nausea—Mitoxantrone—multiple sclerosis	0.000409	0.00106	CcSEcCtD
Dantrolene—Back pain—Methotrexate—multiple sclerosis	0.000406	0.00105	CcSEcCtD
Dantrolene—Fatigue—Betamethasone—multiple sclerosis	0.000406	0.00105	CcSEcCtD
Dantrolene—Fatigue—Dexamethasone—multiple sclerosis	0.000406	0.00105	CcSEcCtD
Dantrolene—Pain—Dexamethasone—multiple sclerosis	0.000403	0.00104	CcSEcCtD
Dantrolene—Pain—Betamethasone—multiple sclerosis	0.000403	0.00104	CcSEcCtD
Dantrolene—Tachycardia—Prednisone—multiple sclerosis	0.0004	0.00103	CcSEcCtD
Dantrolene—Hyperhidrosis—Prednisone—multiple sclerosis	0.000396	0.00102	CcSEcCtD
Dantrolene—Vision blurred—Methotrexate—multiple sclerosis	0.000396	0.00102	CcSEcCtD
Dantrolene—Anorexia—Prednisone—multiple sclerosis	0.000391	0.00101	CcSEcCtD
Dantrolene—Ill-defined disorder—Methotrexate—multiple sclerosis	0.00039	0.00101	CcSEcCtD
Dantrolene—Anaemia—Methotrexate—multiple sclerosis	0.000388	0.001	CcSEcCtD
Dantrolene—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000388	0.001	CcSEcCtD
Dantrolene—Feeling abnormal—Betamethasone—multiple sclerosis	0.000388	0.001	CcSEcCtD
Dantrolene—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000385	0.000995	CcSEcCtD
Dantrolene—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000385	0.000995	CcSEcCtD
Dantrolene—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000382	0.000988	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000382	0.017	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000382	0.017	CbGpPWpGaD
Dantrolene—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000381	0.000986	CcSEcCtD
Dantrolene—Malaise—Methotrexate—multiple sclerosis	0.000379	0.000978	CcSEcCtD
Dantrolene—Leukopenia—Methotrexate—multiple sclerosis	0.000376	0.000971	CcSEcCtD
Dantrolene—Urticaria—Betamethasone—multiple sclerosis	0.000374	0.000967	CcSEcCtD
Dantrolene—Urticaria—Dexamethasone—multiple sclerosis	0.000374	0.000967	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000374	0.000965	CcSEcCtD
Dantrolene—Dizziness—Prednisolone—multiple sclerosis	0.000373	0.000964	CcSEcCtD
Dantrolene—Asthenia—Triamcinolone—multiple sclerosis	0.000372	0.000962	CcSEcCtD
Dantrolene—Abdominal pain—Dexamethasone—multiple sclerosis	0.000372	0.000962	CcSEcCtD
Dantrolene—Abdominal pain—Betamethasone—multiple sclerosis	0.000372	0.000962	CcSEcCtD
Dantrolene—Body temperature increased—Betamethasone—multiple sclerosis	0.000372	0.000962	CcSEcCtD
Dantrolene—Body temperature increased—Dexamethasone—multiple sclerosis	0.000372	0.000962	CcSEcCtD
Dantrolene—Asthenia—Methylprednisolone—multiple sclerosis	0.000371	0.00096	CcSEcCtD
Dantrolene—Insomnia—Prednisone—multiple sclerosis	0.000371	0.000958	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL1B—multiple sclerosis	0.000371	0.0165	CbGpPWpGaD
Dantrolene—Pruritus—Triamcinolone—multiple sclerosis	0.000367	0.000949	CcSEcCtD
Dantrolene—Pruritus—Methylprednisolone—multiple sclerosis	0.000366	0.000947	CcSEcCtD
Dantrolene—Convulsion—Methotrexate—multiple sclerosis	0.000364	0.00094	CcSEcCtD
Dantrolene—Dyspepsia—Prednisone—multiple sclerosis	0.000361	0.000933	CcSEcCtD
Dantrolene—Myalgia—Methotrexate—multiple sclerosis	0.000357	0.000924	CcSEcCtD
Dantrolene—Decreased appetite—Prednisone—multiple sclerosis	0.000356	0.000921	CcSEcCtD
Dantrolene—Rash—Prednisolone—multiple sclerosis	0.000356	0.000919	CcSEcCtD
Dantrolene—Dermatitis—Prednisolone—multiple sclerosis	0.000355	0.000919	CcSEcCtD
Dantrolene—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000354	0.000915	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000354	0.0158	CbGpPWpGaD
Dantrolene—Fatigue—Prednisone—multiple sclerosis	0.000354	0.000913	CcSEcCtD
Dantrolene—Headache—Prednisolone—multiple sclerosis	0.000354	0.000913	CcSEcCtD
Dantrolene—Discomfort—Methotrexate—multiple sclerosis	0.000353	0.000913	CcSEcCtD
Dantrolene—Constipation—Prednisone—multiple sclerosis	0.000351	0.000906	CcSEcCtD
Dantrolene—Confusional state—Methotrexate—multiple sclerosis	0.000346	0.000893	CcSEcCtD
Dantrolene—Dizziness—Triamcinolone—multiple sclerosis	0.000343	0.000887	CcSEcCtD
Dantrolene—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000343	0.000886	CcSEcCtD
Dantrolene—Dizziness—Methylprednisolone—multiple sclerosis	0.000342	0.000885	CcSEcCtD
Dantrolene—Feeling abnormal—Prednisone—multiple sclerosis	0.000338	0.000873	CcSEcCtD
Dantrolene—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000338	0.0151	CbGpPWpGaD
Dantrolene—Asthenia—Betamethasone—multiple sclerosis	0.000338	0.000873	CcSEcCtD
Dantrolene—Asthenia—Dexamethasone—multiple sclerosis	0.000338	0.000873	CcSEcCtD
Dantrolene—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000336	0.000867	CcSEcCtD
Dantrolene—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000335	0.000866	CcSEcCtD
Dantrolene—Nausea—Prednisolone—multiple sclerosis	0.000335	0.000866	CcSEcCtD
Dantrolene—Pruritus—Dexamethasone—multiple sclerosis	0.000333	0.000861	CcSEcCtD
Dantrolene—Pruritus—Betamethasone—multiple sclerosis	0.000333	0.000861	CcSEcCtD
Dantrolene—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000331	0.000856	CcSEcCtD
Dantrolene—Vomiting—Triamcinolone—multiple sclerosis	0.00033	0.000853	CcSEcCtD
Dantrolene—Vomiting—Methylprednisolone—multiple sclerosis	0.000329	0.000851	CcSEcCtD
Dantrolene—Rash—Triamcinolone—multiple sclerosis	0.000327	0.000845	CcSEcCtD
Dantrolene—Dermatitis—Triamcinolone—multiple sclerosis	0.000327	0.000845	CcSEcCtD
Dantrolene—Anorexia—Methotrexate—multiple sclerosis	0.000327	0.000844	CcSEcCtD
Dantrolene—Rash—Methylprednisolone—multiple sclerosis	0.000326	0.000844	CcSEcCtD
Dantrolene—Dermatitis—Methylprednisolone—multiple sclerosis	0.000326	0.000843	CcSEcCtD
Dantrolene—Urticaria—Prednisone—multiple sclerosis	0.000326	0.000842	CcSEcCtD
Dantrolene—Headache—Triamcinolone—multiple sclerosis	0.000325	0.00084	CcSEcCtD
Dantrolene—Headache—Methylprednisolone—multiple sclerosis	0.000324	0.000838	CcSEcCtD
Dantrolene—Abdominal pain—Prednisone—multiple sclerosis	0.000324	0.000838	CcSEcCtD
Dantrolene—Body temperature increased—Prednisone—multiple sclerosis	0.000324	0.000838	CcSEcCtD
Dantrolene—Diarrhoea—Dexamethasone—multiple sclerosis	0.000322	0.000832	CcSEcCtD
Dantrolene—Diarrhoea—Betamethasone—multiple sclerosis	0.000322	0.000832	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000313	0.014	CbGpPWpGaD
Dantrolene—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000312	0.000807	CcSEcCtD
Dantrolene—Dizziness—Dexamethasone—multiple sclerosis	0.000311	0.000805	CcSEcCtD
Dantrolene—Dizziness—Betamethasone—multiple sclerosis	0.000311	0.000805	CcSEcCtD
Dantrolene—Insomnia—Methotrexate—multiple sclerosis	0.00031	0.000801	CcSEcCtD
Dantrolene—Nausea—Triamcinolone—multiple sclerosis	0.000308	0.000796	CcSEcCtD
Dantrolene—Nausea—Methylprednisolone—multiple sclerosis	0.000308	0.000795	CcSEcCtD
Dantrolene—Somnolence—Methotrexate—multiple sclerosis	0.000305	0.000787	CcSEcCtD
Dantrolene—Hypersensitivity—Prednisone—multiple sclerosis	0.000302	0.000781	CcSEcCtD
Dantrolene—Dyspepsia—Methotrexate—multiple sclerosis	0.000302	0.000779	CcSEcCtD
Dantrolene—Vomiting—Dexamethasone—multiple sclerosis	0.000299	0.000774	CcSEcCtD
Dantrolene—Vomiting—Betamethasone—multiple sclerosis	0.000299	0.000774	CcSEcCtD
Dantrolene—Decreased appetite—Methotrexate—multiple sclerosis	0.000298	0.00077	CcSEcCtD
Dantrolene—Rash—Dexamethasone—multiple sclerosis	0.000297	0.000767	CcSEcCtD
Dantrolene—Rash—Betamethasone—multiple sclerosis	0.000297	0.000767	CcSEcCtD
Dantrolene—Dermatitis—Betamethasone—multiple sclerosis	0.000297	0.000766	CcSEcCtD
Dantrolene—Dermatitis—Dexamethasone—multiple sclerosis	0.000297	0.000766	CcSEcCtD
Dantrolene—Fatigue—Methotrexate—multiple sclerosis	0.000295	0.000763	CcSEcCtD
Dantrolene—Headache—Dexamethasone—multiple sclerosis	0.000295	0.000762	CcSEcCtD
Dantrolene—Headache—Betamethasone—multiple sclerosis	0.000295	0.000762	CcSEcCtD
Dantrolene—Asthenia—Prednisone—multiple sclerosis	0.000294	0.00076	CcSEcCtD
Dantrolene—Pain—Methotrexate—multiple sclerosis	0.000293	0.000757	CcSEcCtD
Dantrolene—Pruritus—Prednisone—multiple sclerosis	0.00029	0.00075	CcSEcCtD
Dantrolene—Feeling abnormal—Methotrexate—multiple sclerosis	0.000282	0.00073	CcSEcCtD
Dantrolene—Diarrhoea—Prednisone—multiple sclerosis	0.000281	0.000725	CcSEcCtD
Dantrolene—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.00028	0.000724	CcSEcCtD
Dantrolene—Nausea—Dexamethasone—multiple sclerosis	0.00028	0.000723	CcSEcCtD
Dantrolene—Nausea—Betamethasone—multiple sclerosis	0.00028	0.000723	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL1B—multiple sclerosis	0.000273	0.0122	CbGpPWpGaD
Dantrolene—Urticaria—Methotrexate—multiple sclerosis	0.000272	0.000703	CcSEcCtD
Dantrolene—Dizziness—Prednisone—multiple sclerosis	0.000271	0.000701	CcSEcCtD
Dantrolene—Body temperature increased—Methotrexate—multiple sclerosis	0.000271	0.0007	CcSEcCtD
Dantrolene—Abdominal pain—Methotrexate—multiple sclerosis	0.000271	0.0007	CcSEcCtD
Dantrolene—Vomiting—Prednisone—multiple sclerosis	0.000261	0.000674	CcSEcCtD
Dantrolene—Rash—Prednisone—multiple sclerosis	0.000259	0.000668	CcSEcCtD
Dantrolene—Dermatitis—Prednisone—multiple sclerosis	0.000258	0.000667	CcSEcCtD
Dantrolene—Headache—Prednisone—multiple sclerosis	0.000257	0.000664	CcSEcCtD
Dantrolene—Hypersensitivity—Methotrexate—multiple sclerosis	0.000252	0.000652	CcSEcCtD
Dantrolene—Asthenia—Methotrexate—multiple sclerosis	0.000246	0.000635	CcSEcCtD
Dantrolene—Nausea—Prednisone—multiple sclerosis	0.000244	0.000629	CcSEcCtD
Dantrolene—Pruritus—Methotrexate—multiple sclerosis	0.000242	0.000626	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000242	0.0108	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000242	0.0108	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000239	0.0107	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000239	0.0107	CbGpPWpGaD
Dantrolene—Diarrhoea—Methotrexate—multiple sclerosis	0.000234	0.000606	CcSEcCtD
Dantrolene—Dizziness—Methotrexate—multiple sclerosis	0.000227	0.000586	CcSEcCtD
Dantrolene—Vomiting—Methotrexate—multiple sclerosis	0.000218	0.000563	CcSEcCtD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000217	0.00968	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL6—multiple sclerosis	0.000217	0.00967	CbGpPWpGaD
Dantrolene—Rash—Methotrexate—multiple sclerosis	0.000216	0.000558	CcSEcCtD
Dantrolene—Dermatitis—Methotrexate—multiple sclerosis	0.000216	0.000558	CcSEcCtD
Dantrolene—Headache—Methotrexate—multiple sclerosis	0.000215	0.000555	CcSEcCtD
Dantrolene—Nausea—Methotrexate—multiple sclerosis	0.000204	0.000526	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000196	0.00875	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000196	0.00875	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—multiple sclerosis	0.00016	0.00713	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000153	0.00681	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000125	0.00556	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000113	0.00502	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000104	0.00465	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000104	0.00465	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000103	0.00458	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000103	0.00458	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.45e-05	0.00243	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.42e-05	0.00197	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SRM—multiple sclerosis	2.53e-05	0.00113	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.35e-05	0.00105	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.78e-05	0.000795	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.78e-05	0.000795	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.63e-05	0.000727	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.35e-05	0.000602	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.77e-06	0.000346	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APOE—multiple sclerosis	4.67e-06	0.000208	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—POMC—multiple sclerosis	4.01e-06	0.000179	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALB—multiple sclerosis	3.66e-06	0.000163	CbGpPWpGaD
